RxSight, Inc. (NASDAQ:RXST) Shares Bought by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. raised its position in shares of RxSight, Inc. (NASDAQ:RXST) by 1.9% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 290,754 shares of the company’s stock after acquiring an additional 5,425 shares during the quarter. Charles Schwab Investment Management Inc. owned approximately 0.72% of RxSight worth $9,996,000 as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in RXST. Quarry LP grew its position in shares of RxSight by 82.3% in the third quarter. Quarry LP now owns 638 shares of the company’s stock valued at $32,000 after purchasing an additional 288 shares in the last quarter. Point72 Hong Kong Ltd purchased a new position in shares of RxSight during the third quarter worth $34,000. Private Trust Co. NA acquired a new stake in shares of RxSight in the fourth quarter valued at $34,000. KBC Group NV raised its stake in shares of RxSight by 63.6% in the third quarter. KBC Group NV now owns 1,232 shares of the company’s stock valued at $61,000 after acquiring an additional 479 shares in the last quarter. Finally, Arcadia Investment Management Corp MI acquired a new stake in shares of RxSight in the fourth quarter valued at $46,000. Institutional investors and hedge funds own 78.78% of the company’s stock.

Insider Buying and Selling at RxSight

In related news, Director Jesse Anderson Corley purchased 1,443 shares of RxSight stock in a transaction dated Wednesday, January 15th. The stock was bought at an average cost of $31.18 per share, for a total transaction of $44,992.74. Following the transaction, the director now owns 1,443 shares in the company, valued at approximately $44,992.74. The trade was a ∞ increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Tamara Fountain sold 7,000 shares of RxSight stock in a transaction that occurred on Wednesday, March 12th. The shares were sold at an average price of $25.71, for a total transaction of $179,970.00. Following the sale, the director now owns 24,793 shares of the company’s stock, valued at approximately $637,428.03. The trade was a 22.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 9.36% of the stock is owned by corporate insiders.

RxSight Trading Down 0.2 %

Shares of RXST opened at $24.84 on Friday. RxSight, Inc. has a twelve month low of $24.09 and a twelve month high of $66.54. The stock’s 50 day moving average is $29.63 and its two-hundred day moving average is $40.05. The firm has a market capitalization of $1.01 billion, a PE ratio of -29.93 and a beta of 1.22.

RxSight (NASDAQ:RXST) last announced its quarterly earnings data on Tuesday, February 25th. The company reported ($0.15) earnings per share for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.25). RxSight had a negative net margin of 23.92% and a negative return on equity of 14.00%. The business had revenue of $40.21 million during the quarter, compared to analysts’ expectations of $40.23 million. On average, sell-side analysts predict that RxSight, Inc. will post -0.7 EPS for the current year.

Analysts Set New Price Targets

RXST has been the topic of a number of analyst reports. Needham & Company LLC restated a “buy” rating and issued a $43.00 price target on shares of RxSight in a research note on Wednesday, February 26th. JPMorgan Chase & Co. dropped their price objective on RxSight from $62.00 to $40.00 and set an “overweight” rating on the stock in a report on Wednesday, February 26th. Bank of America dropped their price objective on RxSight from $60.00 to $36.00 and set a “buy” rating on the stock in a report on Friday. UBS Group started coverage on RxSight in a report on Friday, December 6th. They set a “buy” rating and a $52.00 price objective on the stock. Finally, Stifel Nicolaus lowered their price target on RxSight from $33.00 to $28.00 and set a “hold” rating on the stock in a report on Wednesday. Two investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $49.33.

RxSight Profile

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.